Quercetin-crosslinked chitosan nanoparticles: a potential treatment for allergic rhinitis

作者：Dehong Mu, Li Zhou, Lingyu Shi, Ting Liu, Ying Guo, Hao Chen, Hongping Luo, Junhao Ma, Hui Zhang, Peizheng Xiong, Li Tian · 发表于：Scientific Reports · 年份：2024 · DOI：10.1038/s41598-024-54501-2 · 被引用次数：39 · 研究领域：Allergic Rhinitis and Sensitization、Asthma and respiratory diseases、Ocular Surface and Contact Lens

Allergic rhinitis (AR) remains a major health problem worldwide. Compared with traditional oral drugs, nasal administration avoids first-pass metabolism and achieve faster and more effective efficacy. In this study, we used the ion crosslinking method to prepare quercetin-chitosan nasal adaptive nanomedicine (QCS) delivery system and evaluated in the treatment of allergic rhinitis mice models. The obtained positively charged nanoparticles with a particle size of 229.2 ± 0.2 nm have excellent characteristics in encapsulation efficiency (79.604%), drug loading rate (14.068%), drug release (673.068 μg) and stability(> 7 days). Excitingly, QCS treatment significantly reduced the number of sneezing and nasal rubbing events in AR mice, while reducing the levels of inflammatory factors such as immunoglobulin E (IgE), interleukin (IL)-17, tumor necrosis factor (TNF)-α, and (IL)-6 to alleviate AR symptoms. Hematoxylin-eosin (HE) staining also showed the damaged nasal mucosa was improved. These experimental results suggest that QCS can effectively suppress allergic inflammation in a mouse model and hold promise as a therapeutic option for allergic rhinitis.